IDiyas

For the Inventor, By the Inventor

Raedersheim, France

Stéphanie Monnier

USPTO Granted Patents = 10 


 

Average Co-Inventor Count = 4.9

ph-index = 6

Forward Citations = 83(Granted Patents)


Location History:

  • Raedersheiim, FR (2012)
  • Raedersheim, FR (2012 - 2015)

Company Filing History:

goldMedal10 out of 3,923 
 
Novartis Ag
 patents
silverMedal2 out of 8 
 
Novartis Pharma Gmbh
 patents
where one patent can have more than one assignee

Years Active: 2012-2015

Loading Chart...
Loading Chart...
Loading Chart...
10 patents (USPTO):
1. 9163005 - Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide (2015-10-20),
2. 8865897 - [object Object] (2014-10-21),
3. 8829015 - Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide (2014-09-09),
4. 8580806 - Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide (2013-11-12),
5. 8415363 - Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide (2013-04-09),
6. 8389537 - Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide (2013-03-05),
7. 8343984 - Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide (2013-01-01),
8. 8198450 - Quinolinone derivatives and their pharmaceutical compositions (2012-06-12),
9. 8163904 - Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide (2012-04-24),
10. 8119841 - Crystalline forms of aliskiren hemifumarate (2012-02-21),

Title: Stéphanie Monnier: Innovator in Pharmaceutical Chemistry

Introduction

Stéphanie Monnier is a notable inventor based in Raedersheim, France. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 7 patents. His work focuses on innovative solutions for medical treatments, particularly in the area of transplant rejection.

Latest Patents

Among his latest patents are the salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide. These salts are prepared through various processes and represent a new crystalline form of the acetate salt. This invention may be utilized for the prevention or treatment of transplant rejection, showcasing his commitment to advancing medical science.

Career Highlights

Stéphanie Monnier has worked with prominent companies in the pharmaceutical industry, including Novartis AG and Novartis Pharma GmbH. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to the advancement of pharmaceutical products.

Collaborations

Throughout his career, Stéphanie has collaborated with notable individuals such as Paul Allen Sutton and Paul William Manley. These partnerships have further enriched his work and expanded the impact of his inventions.

Conclusion

Stéphanie Monnier is a distinguished inventor whose work in pharmaceutical chemistry has led to significant advancements in medical treatments. His patents and collaborations reflect his dedication to innovation and improving healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…